Sci Rep:先进的放疗技术和剂量增强对根治性前列腺切除术后挽救治疗毒性的影响

2020-01-21 AlexYang MedSci原创

剂量递增放疗与强度调节放疗(IMRT)和成像指导的放疗(IGRT)的安全性和疗效在根治性前列腺切除术后挽救治疗(SRT)中仍旧不清楚。最近,有研究人员调查了这些先进的放疗技术和剂量增强对SRT毒性的影响。他们的多机构回顾性研究包括了421名患者,他们经历了SRT手术,平均剂量为66Gy。IMRT和IGRT分别用于225名患者(53%)和321名患者(T76%)。在平均跟踪调查的50个月中,晚期2级

剂量递增放疗与强度调节放疗(IMRT)和成像指导的放疗(IGRT)的安全性和疗效在根治性前列腺切除术后挽救治疗(SRT)中仍旧不清楚。

最近,有研究人员调查了这些先进的放疗技术和剂量增强对SRT毒性的影响。他们的多机构回顾性研究包括了421名患者,他们经历了SRT手术,平均剂量为66Gy。IMRT和IGRT分别用于225名患者(53%)和321名患者(T76%)。在平均跟踪调查的50个月中,晚期2级或者更高肠道(GI)和泌尿生殖毒性(GU)的累积发生率分别为4.8%和24%。多变量分析阐释了不使用IMRT或者EGRT,或者两者均不使用(HR 3.1, 95%CI 1.8-5.4, p<0.001)和使用全骨盆放疗(HR 7.6, CI 1.0-56, p=0.048)均与晚期GI毒性相关,而更高剂量≥68G是与GU毒性相关的唯一因素(HR 3.1, CI 1.3-7.4, p=0.012)。

最后,研究人员指出,他们的研究表明了SRT中,GI毒性的发生率可以通过IMRT和GRT减少,虽然使用了先进的技术,剂量增强仍旧可能增加GU毒性。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1708856, encodeId=1b9a1e0885636, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Sun Feb 02 00:09:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877244, encodeId=0f8b18e724418, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Jul 23 16:09:00 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487835, encodeId=ca05148e83599, content=<a href='/topic/show?id=46385651633' target=_blank style='color:#2F92EE;'>#挽救治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56516, encryptionId=46385651633, topicName=挽救治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a8374760, createdName=drwjr, createdTime=Thu Jan 23 05:09:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586168, encodeId=4b511586168fa, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Jan 23 05:09:00 CST 2020, time=2020-01-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1708856, encodeId=1b9a1e0885636, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Sun Feb 02 00:09:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877244, encodeId=0f8b18e724418, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Jul 23 16:09:00 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487835, encodeId=ca05148e83599, content=<a href='/topic/show?id=46385651633' target=_blank style='color:#2F92EE;'>#挽救治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56516, encryptionId=46385651633, topicName=挽救治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a8374760, createdName=drwjr, createdTime=Thu Jan 23 05:09:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586168, encodeId=4b511586168fa, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Jan 23 05:09:00 CST 2020, time=2020-01-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1708856, encodeId=1b9a1e0885636, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Sun Feb 02 00:09:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877244, encodeId=0f8b18e724418, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Jul 23 16:09:00 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487835, encodeId=ca05148e83599, content=<a href='/topic/show?id=46385651633' target=_blank style='color:#2F92EE;'>#挽救治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56516, encryptionId=46385651633, topicName=挽救治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a8374760, createdName=drwjr, createdTime=Thu Jan 23 05:09:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586168, encodeId=4b511586168fa, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Jan 23 05:09:00 CST 2020, time=2020-01-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1708856, encodeId=1b9a1e0885636, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Sun Feb 02 00:09:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877244, encodeId=0f8b18e724418, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Jul 23 16:09:00 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487835, encodeId=ca05148e83599, content=<a href='/topic/show?id=46385651633' target=_blank style='color:#2F92EE;'>#挽救治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56516, encryptionId=46385651633, topicName=挽救治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a8374760, createdName=drwjr, createdTime=Thu Jan 23 05:09:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586168, encodeId=4b511586168fa, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Jan 23 05:09:00 CST 2020, time=2020-01-23, status=1, ipAttribution=)]
    2020-01-23 jeanqiuqiu

相关资讯

JAMA:增加蔬菜摄入量与早期前列腺癌患者进展风险

在接受积极监测的早期前列腺癌患者中,增加蔬菜摄入量的行为干预并没有显著降低前列腺癌的进展风险。

Communications Biology:NQO1衰减能够加重前列腺癌和肿瘤细胞的可塑性

NAD (P) H:醌氧化还原酶1(NQO1)能够响应应激来调控细胞命运决定。氧化应激能够支持癌症维持和进展。之前的研究表明了前列腺癌细胞中NQO1(NQO1low)的敲除能够上调促炎细胞因子和激素阻断条件下细胞的生存。最近,有研究人员测试了NQO1low细胞形成肿瘤的能力。研究发现,与NQO1high细胞相比,NQO1low细胞能够形成恶性肿瘤。生物学活检和循环肿瘤细胞表明了前列腺癌的生化复发与

Sci Rep:导管型前列腺癌中HoxB13的表达

前列腺导管型恶性肿瘤(DAC)的组织学标准和选择性生物标记相对与腺泡型恶性肿瘤(AAC)来讲几乎还是未知。之前的研究表明了Hox13遗传变异与前列腺癌的致瘤过程相关。最近,有研究人员调查了HoxB13在前列腺癌中的临床病理特征,并比较了前列腺DAC和AAC的临床病理情况。研究人员通过涂片观察,鉴定了相当于格林森等级3和5的DAC表型编译。研究人员分别在训练集中鉴定了46.5%的案例(46/99)具

Oncogene:BCOR偶联H2A单泛素化来抑制雄激素受体靶标基因来调控前列腺癌增殖

有研究人员已经鉴定了BCL6共阻遏物(BCOR)是一个激素依赖的雄激素受体(AR)互作伴侣,并且是正常前列腺和癌变前列腺发展的关键转录因子。BCOR在癌症和血液疾病中经常突变,并且是非典型多梳抑制复合物1(ncPRC1.1)的组分,对细胞分化的多个方面是需要的。然而,其在雄激素信号或者前列腺癌细胞中的作用仍旧未知。最近,有研究人员利用全基因组分析的方法阐释了在去势难治性前列腺癌(CRPC)中,BC

Clovis的Rubraca超越了多个PARP抑制剂竞争对手,在前列腺癌领域获得FDA的优先审查

FDA刚刚开始对Rubraca(rucaparib)进行为期六个月的优先审查,判决将于5月15日之前完成,用作BRCA1 / 2突变的复发或转移的去势抵抗性前列腺癌(CRPC)成人的单一疗法。BRCA1 / 2基因突变是mCRPC患者最常见的缺陷。

Lancet Oncol:DNA修复基因变异转移去势抵抗性前列腺癌患者中奥拉帕尼治疗研究

转移去势抵抗性前列腺癌富含DNA损伤响应(DDR)基因变异。TOPARP-B试验旨在前瞻性的鉴定DDR基因变异与奥拉帕尼响应在转移去势抵抗性前列腺癌中的相关性。研究有711名患者同意进行靶向筛选,时间为2015年4月1日到2018年8月30日。161名患者具有DDR基因变异,其中98名被随机分配和治疗(每49名进行一种剂量的奥拉帕尼治疗),最后有92名患者的主要治疗终点可以评估(每一种剂量有46名